Insulin Manufacturing in India: Opportunities Pouring In

- NEW DELHI, INDIA, June 29, 2006 - Followed by China, India is the second country in the number of diabetics worldwide. There"re about 30Mn patients of diabetes in India at present, whereas this number is expected to cross 50Mn towards the year 2025.

With leading pharmaceutical majors such as Ranbaxy, Nicholas Piramal, Cipla, Bharat Biotech and Shantha Biotech exploring the possibilities that exist in this sector, the insulin segment in India is heading towards a price war. While Nicholas Piramal is all set to enter the insulin sensitiser segment, the other players including Ranbaxy, Shantha Biotech and Cipla, will make it to the human insulin segment.

Studying the opportunities that exist in this market Levemir, a type of basal insulin, was launched by Novo Nordisk India.

As per a recent market research report named "New Developments in Insulin Delivery Systems (2006)", published by RNCOS, "Growing at an annual rate of 22%, the present value of Insulin market in India is calculated to be around Rs. 3Bn. At present, Levemir (the long acting insulin) is accountable for 10% of the 3.5Bn insulin market in India. It"s expected to take over žth of basal insulin market in India till March 2007".

Reports Highlights

§ Analysis of the current market trends.
§ Comprehensive discussion about the leading edge technologies.
§ Scope of the main insulin delivery systems worldwide.
§ Market projections for the insulin delivery systems
§ Profile discussion of key players in this sector.
§ Overview of various opportunities & challenges in front of the industry.
§ Classification of various actors stimulating the industry.

To purchase your copy: http://www.rncos.com/Report/IM040.htm />For more information about the report please visit www.rncos.com

29.06.2006 - 21:44 Source: 24-7pressrelease.com | Read: 344 X